Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

• Status: Completed
• Trial end date: 2011-06-01

Summary

The primary objective for the 12-week Titration-/Maintenance Period is:

To demonstrate superior efficacy of OXN PR compared to PLA in the improvement of symptom severity of RLS.

• Phase: Phase 3

Details

• Lead Sponsor: Mundipharma Research GmbH & Co KG
• Treatments: Naloxone; Oxycodone